Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...

Merck , known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with background ...

Makerere University, the Uganda Virus Research Institute and the WHO got the Ebola vaccine trial ready for dosing in just ...

MSD's powerhouse PD-1 inhibitor Keytruda (pembrolizumab ... which has been published in the New England Journal of Medicine. The drug has previously been cleared in the UK, Switzerland, and ...

Investing in Innovation Africa (i3), a pan-African initiative to support  African healthtech startups to commercialise and ...

The World Health Organization (WHO) congratulates Niger for having met the criteria for onchocerciasis elimination, making it ...

Lagos, Nigeria. Investing in Innovation Africa (i3), a pan-African initiative to support African healthtech startups to ...

Press Release - The World Health Organization (WHO) congratulates Niger for having met the criteria for onchocerciasis elimination, making it the fifth country globally and the first country in Africa ...

MSD’s sotatercept has become the first FDA ... leading to a better understanding of PAH and the development of a medicine in a novel treatment pathway that expands options for the patient ...